Last Updated : April 22, 2024
Details
Generic Name:
fidaxomicin
Project Status:
Active
Therapeutic Area:
Clostridium difficile infection
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dificid
Project Line:
Reimbursement Review
Project Number:
SF0847-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Request for Advice
Fee Schedule:
N/A
Indications:
Clostridium difficile infection.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | February 05, 2024 |
|---|---|
| Request for Advice received | January 29, 2024 |
| Manufacturer informed of request for advice | January 31, 2024 |
| Manufacturer information or comments due | February 14, 2024 |
| Request for Advice initiated | February 15, 2024 |
| Call for patient/clinician input closed | April 02, 2024 |
| Clarification: - Patient input submission received from the Gastrointestinal Society | |
| Draft CADTH review report(s) sent to sponsor | April 16, 2024 |
| Deadline for sponsors comments | April 25, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | June 14, 2024 |
| Expert committee meeting (initial) | June 26, 2024 |
| Draft recommendation posted for stakeholder feedback | July 18, 2024 |
| End of feedback period | August 01, 2024 |
Last Updated : April 22, 2024